Foundational Overview of HDV

CE / CME

Hepatitis Delta in Focus: A Foundational Overview of HDV

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: December 09, 2022

Expiration: December 08, 2023

Nancy Reau
Nancy Reau, MD

Activity

Progress
1
Course Completed
Therapeutic Targets for HDV Infection

There are many new and exciting therapeutic options on the horizon. This image of the HDV replication cycle highlights novel therapeutic targets.15

One therapeutic target includes entry blockers, like bulevirtide (BLV). Nucleic acid polymers inhibit the release of HBsAg, and experimental agents include REP-2139 and RP-2165. Other immunomodulators that are similar to peginterferon-α are being also investigated, such as peginterferon-λ. Finally, we have prenylation inhibitors that have an impact on the assembly and release of HDV virions; lonafarnib is one such agent being investigated with or without ritonavir.